You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 290 No. 24, December 24/31, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (149)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Oncology
 •Oncology, Other
 •Radiologic Imaging
 •Computed Tomography
 •PET/ SPECT Imaging
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Whole-Body Dual-Modality PET/CT and Whole-Body MRI for Tumor Staging in Oncology

Gerald Antoch, MD; Florian M. Vogt, MD; Lutz S. Freudenberg, MD; Fridun Nazaradeh, MD; Susanne C. Goehde, MD; Jörg Barkhausen, MD; Gerlinde Dahmen, MSc; Andreas Bockisch, MD, PhD; Jörg F. Debatin, MD, MBA; Stefan G. Ruehm, MD

JAMA. 2003;290:3199-3206.

Context  Deciding on the appropriate therapy for patients with malignant diseases mandates accurate tumor staging with whole-body coverage. Magnetic resonance imaging (MRI) and a combined modality including positron emission tomography (PET) and computed tomography (CT) provide whole-body tumor staging in a single session.

Objective  To determine the staging accuracies of both whole-body PET/CT and whole-body MRI for different malignant diseases.

Design, Setting, and Patients  Prospective, blinded, investigator-initiated study of 98 patients (mean age, 58 years; range, 27-94 years) with various oncological diseases who underwent back-to-back whole-body glucose analog [18F]-fluorodeoxyglucose–PET/CT and whole-body MRI for tumor staging. The study was conducted at a university hospital from December 2001 through October 2002 and had a mean follow-up of 273 days (range, 75-515 days). The images were evaluated by 2 different, blinded reader teams. The diagnostic accuracies of the 2 imaging procedures were compared.

Main Outcome Measures  Correct classification of the primary tumor, regional lymph nodes, and distant metastasis (overall TNM stage) using whole-body PET/CT and whole-body MRI. Secondary outcome measures were accurate assessment of T-stage, N-stage, and M-stage by the 2 imaging procedures.

Results  Of 98 patients, the overall TNM stage was correctly determined in 75 with PET/CT (77%; 95% confidence interval [CI], 67%-85%) and in 53 with MRI (54%; 95% CI, 44%-64%) (P<.001). Compared with MRI, PET/CT had a direct impact on patient management in 12 patients. Results from MRI changed the therapy regimen in 2 patients compared with PET/CT. Separate assessment of T-stage (with pathological verification) in 46 patients revealed PET/CT to be accurate in 37 (80%; 95% CI, 66%-91%) and MRI to be accurate in 24 (52%; 95% CI, 37%-67%) (P<.001). Of 98 patients, N-stage was correctly determined in 91 patients with PET/CT (93%; 95% CI, 86%-97%) and in 77 patients with MRI (79%; 95% CI, 69%-86%) (P = .001). Both imaging procedures showed a similar performance in detecting distant metastases.

Conclusions  The feasibility and diagnostic accuracy of the whole-body staging strategies of PET/CT and MRI are established. Superior performance in overall TNM staging suggests the use of [18F]-fluorodeoxyglucose–PET/CT as a possible first-line modality for whole-body tumor staging.


Author Affiliations: Departments of Diagnostic and Interventional Radiology (Drs Antoch, Vogt, Nazaradeh, Goehde, Barkhausen, Debatin, and Ruehm) and Nuclear Medicine (Drs Freudenberg and Bockisch), University Hospital Essen, Essen, Germany; and Institute of Medical Biometry and Statistics, University at Lübeck, Lübeck, Germany (Ms Dahmen).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Whole-Body Imaging for Cancer Staging
Medhat M. Osman
JAMA. 2004;291(11):1320.
EXTRACT | FULL TEXT  

Whole-Body Imaging for Cancer Staging—Reply
Gerald Antoch and Stefan G. Ruehm
JAMA. 2004;291(11):1320.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Whole-Body Imaging With MRI or PET/CT: The Future for Single-Modality Imaging in Oncology?
Lennart Blomqvist and Michael R. Torkzad
JAMA. 2003;290(24):3248-3249.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tissue Classification as a Potential Approach for Attenuation Correction in Whole-Body PET/MRI: Evaluation with PET/CT Data
Martinez-Moller et al.
JNM 2009;50:520-526.
ABSTRACT | FULL TEXT  

Whole-Body MRI Versus PET in Assessment of Multiple Myeloma Disease Activity
Shortt et al.
Am. J. Roentgenol. 2009;192:980-986.
ABSTRACT | FULL TEXT  

Whole-Body MRI and FDG PET Fused Images for Evaluation of Patients with Cancer
Domingues et al.
Am. J. Roentgenol. 2009;192:1012-1020.
ABSTRACT | FULL TEXT  

Breast Cancer Staging in a Single Session: Whole-Body PET/CT Mammography
Heusner et al.
JNM 2008;49:1215-1222.
ABSTRACT | FULL TEXT  

Non-Small Cell Lung Cancer Staging: Efficacy Comparison of Integrated PET/CT versus 3.0-T Whole-Body MR Imaging
Yi et al.
Radiology 2008;248:632-642.
ABSTRACT | FULL TEXT  

Whole-body 18 FDG PET/CT imaging for lymph node and metastatic staging of conjunctival melanoma
Kurli et al.
Br J Ophthalmol 2008;92:479-482.
ABSTRACT | FULL TEXT  

Staging Pathways in Recurrent Colorectal Carcinoma: Is Contrast-Enhanced 18F-FDG PET/CT the Diagnostic Tool of Choice?
Soyka et al.
JNM 2008;49:354-361.
ABSTRACT | FULL TEXT  

Application of PET/CT in the Development of Novel Anticancer Drugs
Boss et al.
The Oncologist 2008;13:25-38.
ABSTRACT | FULL TEXT  

FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy
Veit-Haibach et al.
Br. J. Radiol. 2007;80:508-515.
ABSTRACT | FULL TEXT  

Head and Neck Cancer: Dedicated FDG PET/CT Protocol for Detection--Phantom and Initial Clinical Studies
Yamamoto et al.
Radiology 2007;244:263-272.
ABSTRACT | FULL TEXT  

PET/CT: Form and Function
Blodgett et al.
Radiology 2007;242:360-385.
ABSTRACT | FULL TEXT  

Staging of Primary Malignancies of Bone
Heck et al.
CA Cancer J Clin 2006;56:366-375.
ABSTRACT | FULL TEXT  

Diagnostic Performance of Whole Body Dual Modality 18F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive Patients
Reinhardt et al.
JCO 2006;24:1178-1187.
ABSTRACT | FULL TEXT  

Combined PET/CT colonography: is this the way forward?
Schreyer and Kikinis
Gut 2006;55:10-12.
FULL TEXT  

The contribution of PET/CT to improved patient management
Ell
Br. J. Radiol. 2006;79:32-36.
ABSTRACT | FULL TEXT  

Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer
Veit et al.
Gut 2006;55:68-73.
ABSTRACT | FULL TEXT  

Atherosclerotic Disease: Whole-Body Cardiovascular Imaging with MR System with 32 Receiver Channels and Total-Body Surface Coil Technology--Initial Clinical Results
Fenchel et al.
Radiology 2005;238:280-291.
ABSTRACT | FULL TEXT  

18F-FDG Uptake in an Ovary Containing a Hemorrhagic Corpus Luteal Cyst: False-Positive PET/CT in a Patient with Cervical Carcinoma
Ames et al.
Am. J. Roentgenol. 2005;185:1057-1059.
FULL TEXT  

Whole body PET/CT for initial staging of choroidal melanoma
Finger et al.
Br J Ophthalmol 2005;89:1270-1274.
ABSTRACT | FULL TEXT  

Clinically Significant Incidental Findings on the Unenhanced CT Portion of PET/CT Studies: Frequency in 250 Patients
Osman et al.
JNM 2005;46:1352-1355.
ABSTRACT | FULL TEXT  

Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities
Even-Sapir
JNM 2005;46:1356-1367.
ABSTRACT | FULL TEXT  

Head and Neck Malignancy: Is PET/CT More Accurate than PET or CT Alone?
Branstetter et al.
Radiology 2005;235:580-586.
ABSTRACT | FULL TEXT  

The Value of 18F-FDG PET in the Detection of Stage M0 Carcinoma of the Nasopharynx
Yen et al.
JNM 2005;46:405-410.
ABSTRACT | FULL TEXT  

Accuracy of Whole-Body Dual-Modality Fluorine-18-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Tumor Staging in Solid Tumors: Comparison With CT and PET
Antoch et al.
JCO 2004;22:4357-4368.
ABSTRACT | FULL TEXT  

Cisplatin, Fluorouracil, and Leucovorin Induction Chemotherapy Followed by Concurrent Cisplatin Chemoradiotherapy for Organ Preservation and Cure in Patients With Advanced Head and Neck Cancer: Long-Term Follow-Up
Psyrri et al.
JCO 2004;22:3061-3069.
ABSTRACT | FULL TEXT  

Bone Imaging in Metastatic Breast Cancer
Hamaoka et al.
JCO 2004;22:2942-2953.
ABSTRACT | FULL TEXT  

Whole-Body Imaging for Cancer Staging
Osman
JAMA 2004;291:1320-1320.
FULL TEXT  

Whole-Body Imaging With MRI or PET/CT: The Future for Single-Modality Imaging in Oncology?
Blomqvist and Torkzad
JAMA 2003;290:3248-3249.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.